<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Lamivudine Teva Pharma B.V., INN-lamivudine</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
h3
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	line-height:normal;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-22.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:16.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	line-height:normal;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	line-height:13.0pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	text-align:justify;
	line-height:normal;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:-.1pt;
	margin-bottom:0in;
	margin-left:28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	line-height:13.0pt;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{margin:0in;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{margin:0in;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:35.4pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-indent:-21.25pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	line-height:normal;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Action, li.Action, div.Action
	{mso-style-name:Action;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.35pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Helvetica",sans-serif;}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:black;
	font-style:italic;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Helvetica",sans-serif;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA>SUMMARY OF PRODUCT CHARACTERISTICS</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. 150 mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. 300 mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Lamivudine
Teva Pharma B.V. 150 mg film-coated tablets</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film-coated
tablet contains 150 mg lamivudine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Lamivudine
Teva Pharma B.V. 300 mg film-coated tablets</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film-coated
tablet contains 300 mg lamivudine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
<span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Film-coated
tablet</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Lamivudine
Teva Pharma B.V. 150 mg film-coated tablets</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Light grey, diamond shaped, biconvex film-coated tablet
with approx. 14.5&nbsp;mm length and 7.0&nbsp;mm width &#8211; engraved with
&#8220;L&nbsp;150&#8221; and breakline on one side and breakline on the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The tablet can
be divided into equal doses.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Lamivudine
Teva Pharma B.V. 300 mg film-coated tablets</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Grey, diamond
shaped, biconvex film-coated tablet with approx. 18.0&nbsp;mm length and 8.0&nbsp;mm
width &#8211; engraved with &#8220;L&nbsp;300&#8221; on one side and plain on
the other</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. is indicated as part of antiretroviral combination therapy for the
treatment of Human Immunodeficiency Virus (HIV) infected adults and children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.2<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Posology and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The therapy
should be initiated by a physician experienced in the management of HIV infection.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Lamivudine is also available as an oral solution for children over
three months of age and who weigh less than 14 kg or for patients who are
unable to swallow tablets (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Patients changing
between lamivudine oral solution and lamivudine tablets should follow the
dosing recommendations that are specific for the formulation (see section 5.2)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Adults, adolescents and children (weighing at least 25&nbsp;kg)</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The recommended dose of lamivudine is 300&nbsp;mg daily. This may be
administered as either 150&nbsp;mg twice daily or 300&nbsp;mg once daily (see
section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The 300&nbsp;mg tablet is only suitable for the once a day regimen.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Children (weighing less than 25&nbsp;kg)</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Dosing according to weight bands is recommended for </span><span
lang=EN-GB>Lamivudine Teva Pharma B.V. </span><span lang=EN-GB>tablets.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Children weighing &#8805;20&nbsp;kg to &lt;25&nbsp;kg:</span></i><span
lang=EN-GB> The recommended dose is 225&nbsp;mg daily. This may be administered
as either 75&nbsp;mg (one-half of a 150&nbsp;mg tablet) taken in the morning
and 150&nbsp;mg (one whole 150&nbsp;mg tablet) taken in the evening, or 225&nbsp;mg
(one and a half 150&nbsp;mg tablets) taken once daily.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Children weighing 14&nbsp;kg to &lt;20&nbsp;kg:</span></i><span
lang=EN-GB> The recommended dose is 150&nbsp;mg daily. This may be administered
as 75&nbsp;mg (one-half of a 150&nbsp;mg tablet) taken twice daily, or 150&nbsp;mg
(one whole 150&nbsp;mg tablet) taken once daily.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Children from three months of age:</span></i><span lang=EN-GB> As an
accurate dosage cannot be achieved with the 300&nbsp;mg non-scored tablet
formulation in this patient population, it is recommended that the </span><span
lang=EN-GB>Lamivudine Teva Pharma B.V. </span><span lang=EN-GB>150&nbsp;mg
scored tablet formulation is used and the corresponding recommended dosage
instructions are followed.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Children less than three months of age:</span></i><span lang=EN-GB> The
limited data available are insufficient to propose specific dosage
recommendations (see section 5.2).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Patients changing from the twice daily dosing regimen to the once
daily dosing regimen should take the recommended once daily dose (as described
above) approximately 12&nbsp;hours after the last twice daily dose, and then
continue to take the recommended once daily dose (as described above) approximately
every 24&nbsp;hours. When changing back to a twice daily regimen, patients
should take the recommended twice daily dose approximately 24&nbsp;hours after
the last once daily dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB style='color:black'>Special populations</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB style='color:black'>Older people:</span></i><span lang=EN-GB
style='color:black'> </span><span lang=EN-GB>No specific data are available; however,
special care is advised in this age group due to age-associated changes such as
the decrease in renal function and alteration of haematological parameters.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Renal
impairment:</span></i><span lang=EN-GB> </span><span lang=EN-GB>Lamivudine
concentrations are increased in patients with moderate - severe renal
impairment due to decreased clearance. The dose should therefore be adjusted,</span><span
lang=EN-GB style='color:black'> using an oral solution presentation of
lamivudine for patients whose creatinine clearance falls below 30&nbsp;ml/min
(see tables).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Dosing recommendations &#8211; Adults, adolescents and children
(weighing at least 25&nbsp;kg):</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Creatinine clearance (ml/min)</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>First dose</span></b></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Maintenance dose</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:26.05pt'>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-family:Symbol;color:black'>&sup3;</span><span lang=EN-GB
  style='color:black'>50</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>300&nbsp;mg</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>or</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>150&nbsp;mg</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>300&nbsp;mg once daily</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>or</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>150&nbsp;mg twice daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>30-&lt;50</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>150&nbsp;mg</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>150&nbsp;mg once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&lt;30</span></p>
  </td>
  <td width=283 colspan=2 valign=top style='width:212.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>As doses below 150&nbsp;mg are needed the use of an oral
  solution is recommended</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>15 to &lt;30</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>150&nbsp;mg</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>100&nbsp;mg once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>5 to &lt;15</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>150&nbsp;mg</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>50&nbsp;mg once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&lt;5</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>50&nbsp;mg</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>25&nbsp;mg once daily</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>There are no data available on the use of lamivudine in children
with renal impairment. Based on the assumption that creatinine clearance and
lamivudine clearance are correlated similarly in children as in adults it is
recommended that the dosage in children with renal impairment be reduced
according to their creatinine clearance by the same proportion as in adults. A
10&nbsp;mg/mL oral solution may be the most appropriate formulation to achieve
the recommended dose in </span><span lang=EN-GB style='color:black'>children
with renal impairment aged at least 3 months and weighing less than 25kg</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Dosing recommendations &#8211; Children aged at least
3</span><span lang=EN-GB style='color:black'>&nbsp;</span></i><i><span
lang=EN-GB>months and weighing less than 25</span><span lang=EN-GB
style='color:black'>&nbsp;</span></i><i><span lang=EN-GB>kg:</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='color:black'>Creatinine clearance (ml/min)</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='color:black'>First dose</span></b></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='color:black'>Maintenance dose</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:26.05pt'>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-family:Symbol;color:black'>&sup3;</span><span lang=EN-GB
  style='color:black'>50</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>10&nbsp;mg/kg</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>or</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>5&nbsp;mg/kg</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>10&nbsp;mg/kg once daily</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>or</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>5&nbsp;mg/kg twice daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>30 to&lt;50</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>5&nbsp;mg/kg</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>5&nbsp;mg/kg once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>15 to &lt;30</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>5&nbsp;mg/kg</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>3.3&nbsp;mg/kg once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>5 to &lt;15</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>5&nbsp;mg/kg</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>1.6&nbsp;mg/kg once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&lt;5</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>1.6&nbsp;mg/kg</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>0.9&nbsp;mg/kg once daily</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Hepatic
impairment:</span></i><span lang=EN-GB> </span><span lang=EN-GB>Data obtained
in patients with moderate to severe hepatic impairment shows that lamivudine
pharmacokinetics are not significantly affected by hepatic dysfunction. Based
on these data, no dose adjustment is necessary in patients with moderate or
severe hepatic impairment unless accompanied by renal impairment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. may be administered with or without food.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>To ensure the
administration of the entire dose, the tablet(s) should ideally be swallowed
without crushing.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Alternatively, for
patients who are unable to swallow tablets, the tablet(s) may be crushed and
added to a small amount of semi-solid food or liquid, all of which should be
consumed immediately (see section 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</b></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients </span><span lang=EN-GB
style='color:black'>listed in section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>While effective
viral suppression with antiretroviral therapy has been proven to substantially
reduce the risk of sexual transmission, a residual risk cannot be excluded. Precautions
to prevent transmission should be taken in accordance with national guidelines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. is not recommended for use as monotherapy.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Renal
impairment:</span></i><span lang=EN-GB> In patients with moderate to severe
renal impairment, the terminal plasma half-life of lamivudine is increased due
to decreased clearance; therefore the dose should be adjusted (see section
4.2).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Triple
nucleoside therapy:</span></i><span lang=EN-GB> There have been reports of a
high rate of virological failure and of emergence of resistance at an early
stage when lamivudine was combined with tenofovir disoproxil fumarate and
abacavir as well as with tenofovir disoproxil fumarate and didanosine as a once
daily regimen.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Opportunistic
infections:</span></i><span lang=EN-GB> Patients receiving Lamivudine Teva
Pharma B.V. or any other antiretroviral therapy may continue to develop
opportunistic infections and other complications of HIV infection, and
therefore should remain under close clinical observation by physicians
experienced in the treatment of patients with associated HIV diseases.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Pancreatitis</span></i><span
lang=EN-GB>: Cases of pancreatitis have occurred rarely. However it is not
clear whether these cases were due to the antiretroviral treatment or to the
underlying HIV disease. Treatment with Lamivudine Teva Pharma B.V. should be
stopped immediately if clinical signs, symptoms or laboratory abnormalities
suggestive of pancreatitis occur.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Mitochondrial dysfunction following exposure in utero:</span></i><span
lang=EN-GB> Nucleoside and nucleotide analogues may impact mitochondrial
function to a variable degree, which is most pronounced with stavudine,
didanosine and zidovudine. There have been reports of mitochondrial dysfunction
in HIV-negative infants exposed in utero and/or post-natally to nucleoside
analogues; these have predominantly concerned treatment with regimens
containing zidovudine. The main adverse reactions reported are haematological
disorders (anaemia, neutropenia) and metabolic disorders (hyperlactatemia, hyperlipasemia).
These events have often been transitory. Late-onset neurological disorders have
been reported rarely (hypertonia, convulsion, abnormal behaviour). Whether such
neurological disorders are transient or permanent is currently unknown. These findings
should be considered for any child exposed in utero to nucleoside and
nucleotide analogues, who presents with severe clinical findings of unknown
etiology, particularly neurologic findings. These findings do not affect
current national recommendations to use antiretroviral therapy in pregnant
women to prevent vertical transmission of HIV.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Weight and metabolic parameters:</span></i><span lang=EN-GB> An
increase in weight and in levels of blood lipids and glucose may occur during
antiretroviral therapy. Such changes may in part be linked to disease control
and life style. For lipids, there is in some cases evidence for a treatment
effect, while for weight gain there is no strong evidence relating this to any
particular treatment. For monitoring of blood lipids and glucose reference is
made to established HIV treatment guidelines. Lipid disorders should be managed
as clinically appropriate.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Immune
Reactivation Syndrome:</span></i><span lang=EN-GB> In HIV-infected patients
with severe immune deficiency at the time of institution of combination
antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or
residual opportunistic pathogens may arise and cause serious clinical
conditions, or aggravation of symptoms. Typically, such reactions have been
observed within the first few weeks or months of initiation of CART. Relevant
examples are cytomegalovirus retinitis, generalised and/or focal mycobacterium
infections, and <i>Pneumocystis </i></span><i><span lang=EN-GB>jirovecii</span></i><span
lang=EN-GB> </span><span lang=EN-GB>pneumonia (often referred to as PCP). Any
inflammatory symptoms should be evaluated and treatment instituted when
necessary. Autoimmune disorders (such as Graves&#8217; disease and autoimmune
hepatitis) have also been reported to occur in the setting of immune
reactivation; however, the reported time to onset is more variable and these
events can occur many months after initiation of treatment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Liver
disease: </span></i><span lang=EN-GB>If lamivudine is being used concomitantly
for the treatment of HIV and HBV, additional information relating to the use of
lamivudine in the treatment of hepatitis B infection is available in the
lamivudine 100&nbsp;mg SmPC.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
chronic hepatitis B or C and treated with combination antiretroviral therapy
are at an increased risk of severe and potentially fatal hepatic adverse
events. In case of concomitant antiviral therapy for hepatitis B or C, please
refer also to the relevant product information for these medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If Lamivudine
Teva Pharma B.V. is discontinued in patients co-infected with hepatitis B
virus, periodic monitoring of liver function tests and markers of HBV
replication is recommended, as withdrawal of lamivudine may result in an acute
exacerbation of hepatitis (see lamivudine 100&nbsp;mg SmPC).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
pre-existing liver dysfunction, including chronic active hepatitis, have an
increased frequency of liver function abnormalities during combination
antiretroviral therapy, and should be monitored according to standard practice.
If there is evidence of worsening liver disease in such patients, interruption
or discontinuation of treatment must be considered (see section 4.8).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Paediatric population:</span></i><span lang=EN-GB> In a study
performed in paediatric patients (see section 5.1 ARROW study), lower rates of
virologic suppression and more frequent viral resistance were reported in
children receiving an oral solution of lamivudine as compared to those
receiving the tablet formulation. Whenever possible in children, lamivudine as
tablet formulation should preferably be used.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Osteonecrosis:</span></i><span
lang=EN-GB> Although the etiology is considered to be multifactorial (including
corticosteroid use, alcohol consumption, severe immunosuppression, higher body
mass index), cases of osteonecrosis have been reported particularly in patients
with advanced HIV-disease and/or long-term exposure to combination
antiretroviral therapy (CART). Patients should be advised to seek medical
advice if they experience joint aches and pain, joint stiffness or difficulty
in movement.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Drug
Interactions:</span></i><span lang=EN-GB> Lamivudine Teva Pharma B.V. should
not be taken with any other medicinal products containing lamivudine or
medicinal products containing emtricitabine (see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>The combination of lamivudine with cladribine is
not-recommended (see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span style='color:#222222;
background:white'>Excipient(s)</span></u></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><i>Sodium</i></p>

<p class=MsoNormal style='line-height:normal'>This medicine contains less than
1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially
&#8220;sodium-free&#8221;.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other
medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interaction
studies have only been performed in adults.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The likelihood
of metabolic interactions is low due to limited metabolism and plasma protein
binding and almost complete renal clearance.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of trimethoprim/sulfamethoxazole 160&nbsp;mg/800&nbsp;mg results in a 40%
increase in lamivudine exposure, because of the trimethoprim component; the
sulfamethoxazole component did not interact. However, unless the patient has
renal impairment, no dosage adjustment of lamivudine is necessary (see section
4.2). Lamivudine has no effect on the pharmacokinetics of trimethoprim or
sulfamethoxazole. When concomitant administration is warranted, patients should
be monitored clinically. Co-administration of lamivudine with high doses of
co-trimoxazole for the treatment of <i>Pneumocystis </i></span><i><span
lang=EN-GB style='color:black'>jirovecii</span></i><span lang=EN-GB
style='color:black'> </span><span lang=EN-GB>pneumonia (PCP) and toxoplasmosis
should be avoided.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The possibility
of interactions with other medicinal products administered concurrently should
be considered, particularly when the main route of elimination is active renal
secretion via the organic cationic transport system e.g. trimethoprim. Other
medicinal products (e.g. ranitidine, cimetidine) are eliminated only in part by
this mechanism and were shown not to interact with lamivudine. The nucleoside
analogues (e.g. didanosine) like zidovudine, are not eliminated by this mechanism
and are unlikely to interact with lamivudine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A modest
increase in C<sub>max</sub> (28%) was observed for zidovudine when administered
with lamivudine, however overall exposure (AUC) is not significantly altered.
Zidovudine has no effect on the pharmacokinetics of lamivudine (see section
5.2).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Due to similarities, Lamivudine Teva Pharma B.V. should not
be administered concomitantly with other cytidine analogues, such as
emtricitabine. Moreover, Lamivudine Teva Pharma B.V. should not be taken with
any other medicinal products containing lamivudine (see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:black'>In vitro</span></i><span lang=EN-GB style='color:black'>
lamivudine inhibits the intracellular phosphorylation of cladribine leading to
a potential risk of cladribine loss of efficacy in case of combination in the
clinical setting. Some clinical findings also support a possible interaction
between lamivudine and cladribine. Therefore, the concomitant use of lamivudine
with cladribine is not recommended (see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine
metabolism does not involve CYP3A, making interactions with medicinal products
metabolised by this system (e.g. PIs) unlikely.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Coadministration of
sorbitol solution (3.2&nbsp;g, 10.2&nbsp;g, 13.4&nbsp;g) with a single
300&nbsp;mg dose of lamivudine oral solution resulted in dose-dependent
decreases of 14%, 32%, and 36% in lamivudine exposure (AUC</span><sub><span
lang=EN-GB style='font-family:Symbol;color:black'>&yen;</span></sub><span
lang=EN-GB style='color:black'>) and 28%, 52%, and 55% in the C<sub>max </sub>of
lamivudine in adults. When possible, avoid chronic coadministration of </span><span
lang=EN-GB>Lamivudine Teva Pharma B.V. <span style='color:black'>with medicinal
products containing sorbitol or other osmotic acting poly-alcohols or monosaccharide
alcohols (e.g. xylitol, mannitol, lactitol, maltitol). Consider more frequent
monitoring of HIV-1 viral load when chronic coadministration cannot be avoided.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>Fertility, </span><span lang=EN-GB>pregnancy and
lactation</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As a general
rule, when deciding to use antiretroviral agents for the treatment of HIV
infection in pregnant women and consequently for reducing the risk of HIV
vertical transmission to the newborn, the animal data as well as the clinical
experience in pregnant women should be taken into account. Animal studies with
lamivudine showed an increase in early embryonic deaths in rabbits but not in
rats (see section 5.3). Placental transfer of lamivudine has been shown to
occur in humans.</span></p>

<p style='line-height:normal'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>More than 1000
outcomes from first trimester and more than 1000 outcomes from second and third
trimester exposure in pregnant women indicate no malformative and
foeto/neonatal effect. Lamivudine Teva Pharma B.V. can be used during pregnancy
if clinically needed. <span style='color:black'>The malformative risk is
unlikely in humans based on those data.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For patients
co-infected with hepatitis who are being treated with lamivudine and
subsequently become pregnant, consideration should be given to the possibility
of a recurrence of hepatitis on discontinuation of lamivudine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:black'>Mitochondrial dysfunction:</span></i><span lang=EN-GB
style='color:black'> Nucleoside and nucleotide analogues have been demonstrated
in vitro and in vivo to cause a variable degree of mitochondrial damage. There
have been reports of mitochondrial dysfunction in infants exposed in utero
and/or post-natally to nucleoside analogues (see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Following oral
administration lamivudine was excreted in breast milk at similar concentrations
to those found in serum. <span style='color:black'>Based on more than 200&nbsp;mother/child
pairs treated for HIV, serum concentrations of lamivudine in breastfed infants
of mothers treated for HIV are very low </span>(&lt;4<span style='color:black'>%
of maternal serum concentrations) and progressively decrease to undetectable
levels when breastfed infants reach 24&nbsp;weeks of age. There are no data
available on the safety of lamivudine when administered to babies less than
three months old. </span>It is recommended that HIV infected women do not
breast-feed their infants under any circumstances in order to avoid
transmission of HIV.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;layout-grid-mode:line'>Studies in animals showed that
lamivudine had no effect on fertility (see section 5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to
drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No studies on
the effects on the ability to drive and use machines have been performed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.8<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
adverse reactions have been reported during therapy for HIV disease with
lamivudine:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The adverse
reactions considered at least possibly related to the treatment are listed
below by body system, organ class and absolute frequency. Frequencies are
defined as very common (&#8805;1/10), common (&#8805;1/100 to &lt;1/10),
uncommon (&#8805;1/1,000 to &lt;1/100), rare (&#8805;1/10,000 to &lt;1/1,000),
very rare (&lt;1/10,000). Within each frequency grouping, undesirable effects
are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Blood and
lymphatic systems disorders</span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Uncommon</span></i><i><span
lang=EN-GB>:</span></i><span lang=EN-GB> Neutropenia and anaemia (both
occasionally severe), thrombocytopenia.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Very rare</span></i><i><span
lang=EN-GB>:</span></i><span lang=EN-GB> Pure red cell aplasia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Metabolism and nutrition disorders</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Very rare:</span></i><span lang=EN-GB> Lactic acidosis.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Nervous
system disorders</span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Common: </span></i><span
lang=EN-GB>Headache, insomnia.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Very rare:</span></i><span
lang=EN-GB> Peripheral neuropathy (or paraesthesia).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Respiratory, thoracic and mediastinal disorders</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Common:</span></i><span lang=EN-GB> Cough, nasal symptoms.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Gastrointestinal
disorders</span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Common: </span></i><span
lang=EN-GB>Nausea, vomiting, abdominal pain or cramps, diarrhoea.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Rare:</span></i><span
lang=EN-GB> Pancreatitis, elevations in serum amylase.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Hepatobiliary
disorders</span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Uncommon:</span></i><span
lang=EN-GB> Transient elevations in liver enzymes (AST, ALT).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Rare:</span></i><span lang=EN-GB> Hepatitis.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Skin and
subcutaneous tissue disorders</span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Common:</span></i><span
lang=EN-GB> Rash, alopecia.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Rare: </span></i><span
lang=EN-GB>Angioedema.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Musculoskeletal
and connective tissue disorders</span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Common: </span></i><span
lang=EN-GB>Arthralgia, muscle disorders.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Rare:</span></i><span
lang=EN-GB> Rhabdomyolysis.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>General
disorders and administration site conditions</span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Common:</span></i><span
lang=EN-GB> Fatigue, malaise, fever.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Weight and levels of blood lipids and glucose may increase during antiretroviral
therapy (see section 4.4)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In HIV-infected
patients with severe immune deficiency at the time of initiation of combination
antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or
residual opportunistic infections may arise. </span><span lang=EN-GB>Autoimmune
disorders (such as Graves&#8217; disease</span><span lang=EN-GB> and autoimmune
hepatitis</span><span lang=EN-GB>) have also been reported to occur in the
setting of immune reactivation; however, the reported time to onset is more
variable and these events can occur many months after initiation of treatment </span><span
lang=EN-GB>(see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
osteonecrosis have been reported, particularly in patients with generally
acknowledged risk factors, advanced HIV disease or long-term combined
antiretroviral exposure (CART). The frequency of which is unknown (see section
4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1206
HIV-infected paediatric patients aged 3 months to 17 years were enrolled in the
ARROW Trial (COL105677), 669 of whom received abacavir and lamivudine either
once or twice daily (see section 5.1). No additional safety issues have been
identified in paediatric subjects receiving either once or twice daily dosing
compared to adults.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:lightgrey'>the national reporting
system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of lamivudine at very high dose levels in acute animal studies did not result
in any organ toxicity. Limited data are available on the consequences of
ingestion of acute overdoses in humans. No fatalities occurred, and the
patients recovered. No specific signs or symptoms have been identified
following such overdose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If overdosage
occurs the patient should be monitored, and standard supportive treatment
applied as required. Since lamivudine is dialysable, continuous haemodialysis
could be used in the treatment of overdosage, although this has not been
studied.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: nucleoside analogue, ATC Code: J05AF05.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine is a
nucleoside analogue which has activity against human immunodeficiency virus
(HIV) and hepatitis B virus (HBV). It is metabolised intracellularly to the
active moiety, lamivudine 5&#8217;&#8209;triphosphate. Its main mode of action
is as a chain terminator of viral reverse transcription. The triphosphate has
selective inhibitory activity against HIV&#8209;1 and HIV&#8209;2 replication <i>in
vitro</i>,<i> </i>it is also active against zidovudine-resistant clinical
isolates of HIV. </span><span lang=EN-GB style='color:black'>No antagonistic
effects <i>in vitro</i> were seen with lamivudine and other anti retrovirals
(tested agents: abacavir, didanosine, nevirapine and zidovudine).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Resistance</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>HIV&#8209;1
resistance to lamivudine involves the development of a M184V amino acid change
close to the active site of the viral reverse transcriptase (RT). This variant
arises both <i>in vitro</i> and in HIV&#8209;1 infected patients treated with
lamivudine-containing antiretroviral therapy. M184V mutants display greatly
reduced susceptibility to lamivudine and show diminished viral replicative
capacity <i>in vitro</i>.<i> In vitro</i> studies indicate that
zidovudine-resistant virus isolates can become zidovudine sensitive when they
simultaneously acquire resistance to lamivudine. The clinical relevance of such
findings remains, however, not well defined.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>In vitro</span></i><span
lang=EN-GB> data tend to suggest that the continuation of lamivudine in
anti-retroviral regimen despite the development of M184V might provide residual
anti-retroviral activity (likely through impaired viral fitness). The clinical
relevance of these findings is not established. Indeed, the available clinical
data are very limited and preclude any reliable conclusion in the field. In any
case, initiation of susceptible NRTI&#8217;s should always be preferred to
maintenance of lamivudine therapy. Therefore, maintaining lamivudine therapy
despite emergence of M184V mutation should only be considered in cases where no
other active NRTI&#8217;s are available.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cross-resistance
conferred by the M184V RT is limited within the nucleoside inhibitor class of
antiretroviral agents. Zidovudine and stavudine maintain their antiretroviral
activities against lamivudine-resistant HIV&#8209;1. Abacavir maintains its
antiretroviral activities against lamivudine-resistant HIV&#8209;1 harbouring
only the M184V mutation. The M184V RT mutant shows a &lt;4-fold decrease in
susceptibility to didanosine; the clinical significance of these findings is
unknown. <i>In vitro</i> susceptibility testing has not been standardised and
results may vary according to methodological factors.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine
demonstrates low cytotoxicity to peripheral blood lymphocytes, to established
lymphocyte and monocyte-macrophage cell lines, and to a variety of bone marrow
progenitor cells <i>in vitro</i>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In clinical
trials, lamivudine in combination with zidovudine<b> </b>has been shown to
reduce HIV&#8209;1 viral load and increase CD4 cell count. Clinical end-point
data indicate that lamivudine in combination with zidovudine, results in a
significant reduction in the risk of disease progression and mortality.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Evidence from
clinical studies shows that lamivudine plus zidovudine<b> </b>delays the
emergence of zidovudine resistant isolates in individuals with no prior
antiretroviral therapy.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine has
been widely used as a component of antiretroviral combination therapy with
other antiretroviral agents of the same class (NRTIs) or different classes
(PIs, non-nucleoside reverse transcriptase inhibitors).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical trial
evidence from paediatric patients receiving lamivudine with other antiretroviral
drugs (abacavir, nevirapine/efavirenz or zidovudine) has shown that the
resistance profile observed in paediatric patients is similar to that observed
in adults, in terms of the genotypic substitutions detected and their relative
frequency.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Children
receiving lamivudine oral solution concomitantly with other antiretroviral oral
solutions in clinical trials developed viral resistance more frequently than
children receiving tablets (see the description of the clinical experience in
paediatric population (ARROW study) and section 5.2).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Multiple drug
antiretroviral therapy containing lamivudine has been shown to be effective in
antiretrovirally-naive patients as well as in patients presenting with viruses
containing the M184V mutations. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The relationship
between <i>in vitro</i> susceptibility of HIV to lamivudine and clinical
response to lamivudine-containing therapy remains under investigation.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine at a
dose of 100&nbsp;mg once daily has also been shown to be effective for the
treatment of adult patients with chronic HBV infection (for details of clinical
studies, see the prescribing information for lamivudine 100&nbsp;mg). However,
for the treatment of HIV infection only a 300&nbsp;mg daily dose of lamivudine
(in combination with other antiretroviral agents) has been shown to be
efficacious.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine has
not been specifically investigated in HIV patients co-infected with HBV.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Once daily
dosing (300&nbsp;mg once a day):</span></i><span lang=EN-GB> a clinical study
has demonstrated the non-inferiority between lamivudine once a day and
lamivudine twice a day containing regimens. These results were obtained in an
antiretroviral na&iuml;ve-population, primarily consisting of asymptomatic HIV
infected patients (CDC stage A).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>Paediatric population:</span></i><span lang=EN-GB> a randomised
comparison of a regimen including once daily vs twice daily dosing of abacavir
and lamivudine was undertaken within a randomised, multicentre, controlled
study of HIV-infected, paediatric patients. 1206&nbsp;paediatric patients aged
3&nbsp;months to 17&nbsp;years enrolled in the ARROW Trial (COL105677) and were
dosed according to the weight-band dosing recommendations in the World Health
Organisation treatment guidelines (Antiretroviral therapy of HIV infection in
infants and children, 2006). After 36&nbsp;weeks on a regimen including twice daily
abacavir and lamivudine, 669 eligible subjects were randomised to either
continue twice daily dosing or switch to once daily abacavir and lamivudine for
at least 96&nbsp;weeks. Of note, from this study clinical data were not
available for children under one year old. The results are summarised in the
table below:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Virological Response Based on Plasma HIV-1 RNA less
than 80&nbsp;copies/ml at Week 48 and Week 96 in the Once Daily versus Twice
Daily abacavir + lamivudine randomisation of ARROW (Observed Analysis)</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=456
 style='width:341.65pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=157 valign=top style='width:117.8pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Twice Daily</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>N (%)</span></b></p>
  </td>
  <td width=147 valign=top style='width:110.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Once Daily</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>N (%)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=456 colspan=3 valign=top style='width:341.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Week 0 (After &#8805;36 Weeks on
  Treatment)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=157 valign=top style='width:117.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=DE>Plasma HIV-1 RNA &lt;80&nbsp;c/mL</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>250/331 (76)</span></p>
  </td>
  <td width=147 valign=top style='width:110.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>237/335 (71)</span></p>
  </td>
 </tr>
 <tr>
  <td width=157 valign=top style='width:117.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>Risk difference (once daily-twice
  daily)</span></p>
  </td>
  <td width=298 colspan=2 valign=top style='width:223.85pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>-4.8% (95% CI -11.5% to +1.9%),
  p=0.16</span></p>
  </td>
 </tr>
 <tr>
  <td width=456 colspan=3 valign=top style='width:341.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Week 48</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=157 valign=top style='width:117.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=DE>Plasma HIV-1 RNA &lt;80&nbsp;c/mL</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>242/331 (73)</span></p>
  </td>
  <td width=147 valign=top style='width:110.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>236/330 (72)</span></p>
  </td>
 </tr>
 <tr>
  <td width=157 valign=top style='width:117.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>Risk difference (once daily-twice
  daily)</span></p>
  </td>
  <td width=298 colspan=2 valign=top style='width:223.85pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>-1.6% (95% CI -8.4% to +5.2%),
  p=0.65</span></p>
  </td>
 </tr>
 <tr>
  <td width=456 colspan=3 valign=top style='width:341.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Week 96</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=157 valign=top style='width:117.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=DE>Plasma HIV-1 RNA &lt;80&nbsp;c/mL</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>234/326 (72)</span></p>
  </td>
  <td width=147 valign=top style='width:110.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>230/331 (69)</span></p>
  </td>
 </tr>
 <tr>
  <td width=157 valign=top style='width:117.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>Risk difference (once daily-twice
  daily)</span></p>
  </td>
  <td width=298 colspan=2 valign=top style='width:223.85pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>-2.3% (95% CI -9.3% to +4.7%),
  p=0.52</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In a pharmacokinetic study (PENTA 15), four virologically controlled
subjects less than 12</span><span lang=EN-GB>&nbsp;months of age switched from
abacavir plus lamivudine oral solution twice daily to a once daily regimen.
Three subjects had undetectable viral load and one had plasmatic HIV-RNA of 900&nbsp;copies/ml
at Week 48. No safety concerns were observed in these subjects.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The abacavir + lamivudine once daily dosing group was demonstrated
to be non-inferior to the twice daily group according to the pre-specified
non-inferiority margin of -12%, for the primary endpoint of &lt;80</span><span
lang=EN-GB>&nbsp;c/mL at Week 48 as well as at Week 96 (secondary endpoint) and
all other thresholds tested (&lt;200&nbsp;c/mL, &lt;400&nbsp;c/mL, &lt;1000&nbsp;c/mL),
which all fell well within this non-inferiority margin. Subgroup analyses testing
for heterogeneity of once vs twice daily demonstrated no significant effect of
sex, age, or viral load at randomisation. Conclusions supported non-inferiority
regardless of analysis method.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>At the time of randomization to once daily vs twice daily dosing
(Week 0), those patients who had received tablet formulations had a higher rate
of viral load suppression than those who had received any solution formulations
at any time. These differences were observed in each different age group
studied. This difference in suppression rates between tablets and solutions
remained through Week 96 with once daily dosing.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Proportions of Subjects in the Once Daily versus Twice Daily
Abacavir+Lamivudine Randomisation of ARROW with Plasma HIV-1 RNA &lt;80&nbsp;copies/ml:
Subgroup Analysis by Formulation</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=559
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=262 valign=top style='width:196.8pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=148 valign=top style='width:111.3pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Twice Daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>Plasma HIV-1 RNA &lt;80&nbsp;c/ml: <br>
  n/N (%)</span></p>
  </td>
  <td width=148 valign=top style='width:111.3pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Once Daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>Plasma HIV-1 RNA &lt;80&nbsp;c/ml: <br>
  n/N (%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=262 valign=top style='width:196.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Week 0 (after 36 weeks on treatment)</span></i></p>
  </td>
  <td width=148 valign=top style='width:111.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=148 valign=top style='width:111.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=262 valign=top style='width:196.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Any solution regimen at any time</span></p>
  </td>
  <td width=148 valign=top style='width:111.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>14/26 (54)</span></p>
  </td>
  <td width=148 valign=top style='width:111.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>15/30 (50)</span></p>
  </td>
 </tr>
 <tr>
  <td width=262 valign=top style='width:196.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>All tablet based regimen throughouts</span></p>
  </td>
  <td width=148 valign=top style='width:111.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>236/305 (77)</span></p>
  </td>
  <td width=148 valign=top style='width:111.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>222/305 (73)</span></p>
  </td>
 </tr>
 <tr>
  <td width=262 valign=top style='width:196.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Week 96</span></i></p>
  </td>
  <td width=148 valign=top style='width:111.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=148 valign=top style='width:111.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=262 valign=top style='width:196.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Any solution regimen at any time</span></p>
  </td>
  <td width=148 valign=top style='width:111.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>13/26 (50)</span></p>
  </td>
  <td width=148 valign=top style='width:111.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>17/30 (57)</span></p>
  </td>
 </tr>
 <tr>
  <td width=262 valign=top style='width:196.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>All tablet based regimen throughouts</span></p>
  </td>
  <td width=148 valign=top style='width:111.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>221/300 (74)</span></p>
  </td>
  <td width=148 valign=top style='width:111.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>213/301 (71)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Genotypic resistance analyses were conducted on samples with plasma
HIV-1 RNA &gt;1000&nbsp;copies/ml. More cases of resistance were detected among
patients who had received lamivudine solution, in combination with other
antiretroviral solutions, compared with those who received similar doses of
tablet formulation. This is consistent with the lower rates of antiviral
suppression observed in these patients.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine is
well absorbed from the gastrointestinal tract, and the bioavailability of oral
lamivudine in adults is normally between 80 and 85%. Following oral
administration, the mean time (t<sub>max</sub>) to maximal serum concentrations
(C<sub>max</sub>) is about an hour. Based on data derived from a study in
healthy volunteers, at a therapeutic dose of 150&nbsp;mg twice daily, mean (CV)
steady-state C<sub>max</sub> and C<sub>min</sub> of lamivudine in plasma are
1.2&nbsp;&micro;g/ml (24%) and 0.09&nbsp;&micro;g/ml (27%), respectively. The
mean (CV) AUC over a dosing interval of 12 hours is 4.7&nbsp;&micro;g&#8226;h/ml
(18%). At a therapeutic dose of 300&nbsp;mg once daily, the mean (CV)
steady-state C<sub>max</sub>, C<sub>min</sub> and 24h AUC are 2.0&nbsp;&micro;g/ml
(26%), 0.04&nbsp;&micro;g/ml (34%) and 8.9&nbsp;&micro;g&#8226;h/ml (21%),
respectively.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The 150&nbsp;mg
tablet is bioequivalent and dose proportional to the 300&nbsp;mg tablet with
respect to AUC<sub>&#8734;</sub>, C<sub>max</sub>, and t<sub>max</sub>.
Administration of lamivudine tablets is bioequivalent to lamivudine oral
solution with respect to AUC<sub>&#8734;</sub> and C<sub>max</sub> in adults.
Absorption differences have been observed between adult and paediatric
populations (see &#8220;Special populations&#8221;).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
of lamivudine with food results in a delay of t<sub>max</sub> and a lower C<sub>max</sub>
(decreased by 47%). However, the extent (based on the AUC) of lamivudine
absorbed is not influenced.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of crushed tablets with a small amount of semi-solid food or liquid would not
be expected to have an impact on the pharmaceutical quality, and would
therefore not be expected to alter the clinical effect. This conclusion is
based on the physicochemical and pharmacokinetic data assuming that the patient
crushes and transfers 100% of the tablet and ingests immediately.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
of zidovudine results in a 13% increase in zidovudine exposure and a 28%
increase in peak plasma levels. This is not considered to be of significance to
patient safety and therefore no dosage adjustments are necessary.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>From intravenous
studies, the mean volume of distribution is 1.3&nbsp;l/kg. The observed
half-life of elimination is 5 to 7&nbsp;hours. The mean systemic clearance of
lamivudine is approximately 0.32&nbsp;l/h/kg, with predominantly renal
clearance (&gt;70%) via the organic cationic transport system.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine
exhibits linear pharmacokinetics over the therapeutic dose range and displays
limited binding to the major plasma protein albumin (&lt;16%&#8209;36% to serum
albumin in <i>in vitro</i> studies).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Limited data
show that lamivudine penetrates the central nervous system and reaches the
cerebro-spinal fluid (CSF). The mean ratio CSF/serum lamivudine concentration
2-4 hours after oral administration was approximately 0.12. The true extent of
penetration or relationship with any clinical efficacy is unknown.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB
style='color:black'>Biotransformation</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The active
moiety, intracellular lamivudine triphosphate, has a prolonged terminal
half-life in the cell (16 to 19&nbsp;hours) compared to the plasma lamivudine
half-life (5 to 7&nbsp;hours). In 60 healthy adult volunteers, lamivudine
300&nbsp;mg once daily has been demonstrated to be pharmacokinetically
equivalent at steady-state to lamivudine 150&nbsp;mg twice daily with respect
to intracellular triphosphate AUC<sub>24</sub> and C<sub>max</sub>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine is
predominately cleared unchanged by renal excretion. The likelihood of metabolic
interactions of lamivudine with other medicinal products is low due to the
small extent of hepatic metabolism (5&#8209;10%) and low plasma protein
binding.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Studies in
patients with renal impairment show lamivudine elimination is affected by renal
dysfunction. A recommended dosage regimen for patients with creatinine
clearance below 50&nbsp;ml/min is shown in the dosage section (see section
4.2).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>An interaction
with trimethoprim, a constituent of co-trimoxazole, causes a 40% increase in
lamivudine exposure at therapeutic doses. This does not require dose adjustment
unless the patient also has renal impairment (see sections 4.5 and 4.2). Administration
of co-trimoxazole with lamivudine in patients with renal impairment should be
carefully assessed.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Children:</span></i><span lang=EN-GB> The absolute bioavailability
of lamivudine (approximately 58-66%) was reduced in paediatric patients below
12&nbsp;years of age. In children, administration of tablets given
concomitantly with other antiretroviral tablets delivered higher plasma
lamivudine AUC<sub>&#8734;</sub> and C<sub>max</sub> than oral solution given
concomitantly with other antiretroviral oral solutions. Children receiving
lamivudine oral solution according to the recommended dosage regimen achieve
plasma lamivudine exposure within the range of values observed in adults.
Children receiving lamivudine oral tablets according to the recommended dosage
regimen achieve higher plasma lamivudine exposure than children receiving oral solution
because higher mg/kg doses are administered with the tablet formulation and the
tablet formulation has higher bioavailability (see section 4.2). Paediatric
pharmacokinetic studies with both oral solution and tablet formulations have
demonstrated that once daily dosing provides equivalent AUC<sub>0-24</sub> to
twice daily dosing of the same total daily dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>There are limited pharmacokinetic data for patients less than three
months of age. In neonates one week of age, lamivudine oral clearance was
reduced when compared to paediatric patients and is likely to be due to
immature renal function and variable absorption. Therefore to achieve similar
adult and paediatric exposure, an appropriate dose for neonates is 4&nbsp;mg/kg/day.
Glomerular filtration estimates suggests that to achieve similar adult and
paediatric exposure, an appropriate dose for children aged six weeks and older
could be 8&nbsp;mg/kg/day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pharmacokinetic data were derived from 3 pharmacokinetic studies
(PENTA 13, PENTA 15 and ARROW PK substudy) enrolling children under 12&nbsp;years
of age. The data are displayed in the table below:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Summary of Stead-State Plasma Lamivudine AUC (0-24) (&micro;g&#8226;h/mL)
and Statistical Comparisons for Once and Twice-Daily Oral Administration Across
Studies</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:.1pt;border-collapse:collapse;border:none'>
 <tr style='height:78.45pt'>
  <td width=125 valign=top style='width:93.55pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:78.45pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b><span lang=EN-GB>Study</span></b></p>
  </td>
  <td width=125 valign=top style='width:93.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:78.45pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b><span lang=EN-GB>Age Group</span></b></p>
  </td>
  <td width=125 valign=top style='width:1.3in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:78.45pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b><span lang=EN-GB>Lamivudine</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b><span lang=EN-GB>8&nbsp;mg/kg Once-Daily Dosing
  Geometric Mean (95% Cl)</span></b></p>
  </td>
  <td width=125 valign=top style='width:1.3in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:78.45pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b><span lang=EN-GB>Lamivudine</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b><span lang=EN-GB>4&nbsp;mg/kg Twice-Daily Dosing
  Geometric Mean (95% Cl)</span></b></p>
  </td>
  <td width=125 valign=top style='width:1.3in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:78.45pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b><span lang=EN-GB>Once-Versus Twice-Daily Comparison
  GLS Mean Ratio (90% Cl)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:93.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>ARROW PK Substudy</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>Part 1</span></p>
  </td>
  <td width=125 valign=top style='width:93.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>3 to 12 years (N=35)</span></p>
  </td>
  <td width=125 valign=top style='width:1.3in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>13.0</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>(11.4,14.9)</span></p>
  </td>
  <td width=125 valign=top style='width:1.3in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>12.0</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>(10.7, 13.4)</span></p>
  </td>
  <td width=125 valign=top style='width:1.3in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>1.09</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>(0.979, 1.20)</span></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:93.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>PENTA 13</span></p>
  </td>
  <td width=125 valign=top style='width:93.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>2 to 12 years (N=19)</span></p>
  </td>
  <td width=125 valign=top style='width:1.3in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>9.80</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>(8.64, 11.1)</span></p>
  </td>
  <td width=125 valign=top style='width:1.3in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>8.88</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>(7.67, 10.3)</span></p>
  </td>
  <td width=125 valign=top style='width:1.3in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>1.12</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>(1.03, 1.21)</span></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:93.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>PENTA 15</span></p>
  </td>
  <td width=125 valign=top style='width:93.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>3 to 36 months (N=17)</span></p>
  </td>
  <td width=125 valign=top style='width:1.3in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>8.66</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>(7.46, 10.1)</span></p>
  </td>
  <td width=125 valign=top style='width:1.3in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>9.48</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>(7.89, 11.40)</span></p>
  </td>
  <td width=125 valign=top style='width:1.3in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>0.91</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB>(0.79, 1.06)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In PENTA 15 study, the geometric mean plasma lamivudine AUC(0-24)
(95% CI) of the four subjects under 12 months of age who switch from a twice
daily to a once daily regimen (see section 5.1) are 10.31 (6.26, 17.0) &micro;g&#8226;h/mL
in the once-daily dosing and 9.24 (4.66, 18.3) &micro;g&#8226;h/mL in the
twice-daily dosing.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Pregnancy:</span></i><span lang=EN-GB> Following oral
administration, lamivudine pharmacokinetics in late-pregnancy were similar to
non-pregnant women.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of lamivudine in animal toxicity studies at high doses was not associated with
any major organ toxicity. At the highest dosage levels, minor effects on
indicators of liver and kidney function were seen together with occasional
reductions in liver weight. The clinically relevant effects noted were a
reduction in red blood cell count and neutropenia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine was
not mutagenic in bacterial tests but, like many nucleoside analogues, showed
activity in an <i>in vitro </i>cytogenetic assay and the mouse lymphoma assay. Lamivudine
was not genotoxic <i>in vivo</i> at doses that gave plasma concentrations
around 40-50 times higher than the anticipated clinical plasma levels. As the <i>in
vitro</i> mutagenic activity of lamivudine could not be confirmed in <i>in vivo</i>
tests, it is concluded that lamivudine should not represent a genotoxic hazard
to patients undergoing treatment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A transplacental
genotoxicity study conducted in monkeys compared zidovudine alone with the
combination of zidovudine and lamivudine at human-equivalent exposures. The
study demonstrated that foetuses exposed <i>in utero</i> to the combination
sustained a higher level of nucleoside analogue-DNA incorporation into multiple
foetal organs, and showed evidence of more telomere shortening than in those
exposed to zidovudine alone. The clinical significance of these findings is
unknown.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The results of
long-term carcinogenicity studies in rats and mice did not show any
carcinogenic potential relevant for humans.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black'>A
fertility study in rats has shown that lamivudine had no effect on male or
female fertility.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Tablet core</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Microcrystalline
cellulose</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium starch
glycolate (Type A)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Magnesium
Stearate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Tablet film
coat</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypromellose 3cP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypromellose 6cP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Titanium dioxide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Macrogol 400</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Polysorbate 80</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Iron oxide
yellow</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Iron oxide black</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2 years</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for
storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product does not require any special storage conditions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>6.5<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Blisters</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White opaque
PVC/PVdC &#8211; Aluminium blisters</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack sizes of
20, 30, 60, 80, 90, 100 or 500 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Tablet containers</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Lamivudine
Teva Pharma B.V. 150 mg film-coated tablets</span></u><span lang=EN-GB>: </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White opaque
HDPE tablet containers with white opaque polyethylene child resistant screw cap
with induction seal</span></p>

<p class=MsoNormal style='line-height:normal'>Pack size of 60 film-coated
tablets</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White opaque
HDPE tablet containers with </span>white opaque polypropylene child resistant,
tamper-evident screw cap with induction seal</p>

<p class=MsoNormal style='line-height:normal'>Pack size of 60 film-coated
tablets</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Lamivudine
Teva Pharma B.V. 300 mg film-coated tablets</span></u><span lang=EN-GB>: </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White opaque
HDPE tablet containers with white opaque polyethylene child resistant screw cap
with induction seal</span></p>

<p class=MsoNormal style='line-height:normal'>Pack size of 30 film-coated
tablets</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White opaque
HDPE tablet containers with </span>white opaque polypropylene child resistant,
tamper-evident screw cap with induction seal</p>

<p class=MsoNormal style='line-height:normal'>Pack size of 30 film-coated
tablets</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not all pack
sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for
disposal</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No special
requirements </span><span lang=EN-GB style='color:black'>for disposal</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva B.V.</span></p>

<p class=MsoNormal style='line-height:normal'>Swensweg 5</p>

<p class=MsoNormal style='line-height:normal'>2031GA Haarlem</p>

<p class=MsoNormal style='line-height:normal'>Netherlands</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION
NUMBER(S)</b></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Lamivudine
Teva Pharma B.V. 150 mg film-coated tablets</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/001&nbsp; 20
tablets (blister)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/002&nbsp; 30
tablets (blister)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/003&nbsp; 60
tablets (blister)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/004&nbsp; 90
tablets (blister)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/005&nbsp; 100
tablets (blister)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/006&nbsp; 500
tablets (blister)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/007&nbsp; 60
tablets (bottle)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/015&nbsp; 80
tablets (blister)</span></p>

<p class=MsoNormal style='line-height:normal'>EU/1/09/596/017&nbsp; 60 tablets
(bottle with tamper-evident cap)</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Lamivudine
Teva Pharma B.V. 300 mg film-coated tablets</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/008&nbsp; 20
tablets (blister)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/009&nbsp; 30
tablets (blister)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/010&nbsp; 60
tablets (blister)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/011&nbsp; 90
tablets (blister)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/012&nbsp; 100
tablets (blister)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/013&nbsp; 500
tablets (blister)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/014&nbsp; 30
tablets (bottle)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/016&nbsp; 80
tablets(blister)</span></p>

<p class=MsoNormal style='line-height:normal'>EU/1/09/596/018&nbsp; 30 tablets
(bottle with tamper-evident cap)</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE OF
FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: 10 December 2009</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal: 11 September 2014</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>{MM/YYYY}</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency </span><span lang=EN-GB><a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span><span
lang=EN-GB style='color:blue'>/.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><u><span
lang=EN-GB style='font-size:10.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><u><span
lang=EN-GB style='font-size:10.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><u><span
lang=EN-GB style='font-size:10.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><u><span
lang=EN-GB style='font-size:10.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><u><span
lang=EN-GB style='font-size:10.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:12.55pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER(S)
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:48.0pt;line-height:normal'><b><span
lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:84.0pt;text-indent:-.5in;line-height:
normal'><b><span lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:12.55pt;margin-bottom:
0in;margin-left:84.75pt;margin-bottom:.0001pt;text-indent:-35.1pt;line-height:
normal'><b><span lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER(S)
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Name and
address of the manufacturer(s) responsible for batch release</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva
Pharmaceutical Works Private Limited Company</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pallagi
&uacute;t 13</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Debrecen H-4042</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hungary</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Pharmachemie B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>2031 GA Haarlem</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The printed
package leaflet of the medicinal product must state the name and address of the
manufacturer responsible for the release of the concerned batch.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to restricted medical prescription (see Annex I: Summary of
Product Characteristics, section 4.2).</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING <span lang=EN-GB>AUTHORISATION</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic safety update reports (PSURs)</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The requirements
for submission of PSURs for this medicinal product are set out in the list of
Union reference dates (EURD list) provided for under Article 107c(7) of
Directive 2001/83/EC and any subsequent updates published on the European
medicines web-portal.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS
WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE <span lang=EN-GB>MEDICINAL</span>
PRODUCT</p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA>A. LABELLING</p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON &#8211; LAMIVUDINE TEVA PHARMA B.V. 150&nbsp;MG FILM-COATED
TABLETS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. 150&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>lamivudine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film-coated
tablet contains 150&nbsp;mg of lamivudine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:white'>20 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#A0A0A0'>30 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#A0A0A0'>60 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#A0A0A0'>80 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#A0A0A0'>90 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#A0A0A0'>100 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#A0A0A0'>500 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Teva B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>2031GA Haarlem</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/002</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/003</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/004</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/005</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/006</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/007</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/015</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/017</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=DE>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. 150&nbsp;mg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#BFBFBF'>2D barcode carrying the unique
identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PC:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>SN:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>NN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:39.25pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>MINIMUM
  PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Immediate
  packaging (blister foil)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. 150&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>lamivudine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TEVA B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>Tablet container &#8211; Lamivudine Teva Pharma B.V. 150&nbsp;mg
film-coated tablets</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. 150&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>lamivudine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film-coated
tablet contains 150&nbsp;mg of lamivudine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:white'>60 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Teva B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>2031GA Haarlem</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>EU/1/09/596/007</p>

<p class=MsoNormal style='line-height:normal'>EU/1/09/596/017</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; HUMAN READABLE
DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON - LAMIVUDINE TEVA PHARMA B.V. 300&nbsp;MG FILM-COATED TABLETS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. 300&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>lamivudine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film-coated
tablet contains 300&nbsp;mg of lamivudine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:white'>20 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#A0A0A0'>30 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#A0A0A0'>60 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#A0A0A0'>80 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#A0A0A0'>90 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#A0A0A0'>100 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#A0A0A0'>500 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNINGS, IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Teva B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>2031GA Haarlem</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/008</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/009</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/010</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/011</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/012</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/014</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/016</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/596/018</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=DE>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. 300&nbsp;mg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#BFBFBF'>2D barcode carrying the unique
identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PC:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>SN:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>NN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:39.25pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>MINIMUM
  PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Immediate
  packaging (blister foil)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. 300&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>lamivudine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TEVA B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>Tablet container &#8211; Lamivudine Teva Pharma B.V. 300mg film-coated
tablets</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. 300&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>lamivudine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film-coated
tablet contains 300&nbsp;mg of lamivudine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:white'>30 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Teva B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>2031GA Haarlem</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>EU/1/09/596/014</p>

<p class=MsoNormal style='line-height:normal'>EU/1/09/596/018</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; HUMAN READABLE
DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA>B. PACKAGE LEAFLET</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB style='color:black'>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Lamivudine Teva Pharma B.V. 150 mg film-coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>lamivudine</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start taking this medicine </span><span
lang=EN-GB style='color:black'>because it contains important information for
you</span><span lang=EN-GB>.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this leaflet. You
may need to read it again.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any further
questions, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This
medicine has been prescribed for you only. Do not pass it on to others. It may
harm them, even if their signs of illness are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get
any side effects </span><span lang=EN-GB style='color:black'>talk to your
doctor or pharmacist. This includes</span><span lang=EN-GB> any possible side
effects not listed in this leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Lamivudine Teva Pharma
B.V. is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB
style='color:black'>What you need to know </span><span lang=EN-GB>before you
take Lamivudine Teva Pharma B.V.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Lamivudine Teva
Pharma B.V.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:
normal'><span lang=EN-GB>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>How to store Lamivudine Teva Pharma B.V.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB
style='color:black'>Contents of the pack and other</span><span lang=EN-GB>
information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What Lamivudine Teva Pharma B.V. is and
what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Lamivudine
Teva Pharma B.V. is used to treat HIV (human immunodeficiency virus) infection
in adults and children.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The active
ingredient in Lamivudine Teva Pharma B.V. is lamivudine. Lamivudine Teva Pharma
B.V. is a type of medicine known as an antiretroviral.</span><span lang=EN-GB> It
belongs to a group of medicines called <i>nucleoside analogue reverse
transcriptase inhibitors (NRTIs)</i>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. does not completely cure HIV infection; it reduces the amount of
virus in your body, and keeps it at a low level. It also increases the CD4 cell
count in your blood. CD4 cells are a type of white blood cells, that</span><span
lang=EN-GB> are important in helping your body to fight infection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not everyone
responds to treatment with Lamivudine Teva Pharma B.V. in the same way. Your
doctor will monitor the effectiveness of your treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB style='color:black'>What you need to know
</span><span lang=EN-GB>before you take Lamivudine Teva Pharma B.V.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not take
Lamivudine Teva Pharma B.V.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are <b>allergic</b> to lamivudine or any
of the other ingredients of this medicine (listed in section 6).</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Check with
your doctor</span></b><span lang=EN-GB> if you think this applies to you.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Warnings and precautions </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Talk to your doctor or pharmacist before taking </span><span
lang=EN-GB>Lamivudine Teva Pharma B.V..</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Some people taking Lamivudine Teva Pharma B.V. or other combination
treatments for HIV are more at risk of serious side effects. You need to be
aware of the extra risks:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol;
color:black'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have ever had <b>liver disease</b>,
including hepatitis B or C (if you have hepatitis B infection, do not stop Lamivudine
Teva Pharma B.V. without your doctor&#8217;s advice, as your hepatitis may come
back)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol;
color:black'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are seriously overweight (especially if
you are a woman)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol;
color:black'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>if you or your child has a kidney problem,</span></b><span
lang=EN-GB> your dose may be altered.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='color:black'>Talk to your doctor if any of these apply to you</span></b><span
lang=EN-GB style='color:black'>. You may need extra check-ups, including blood
tests, while you are taking your medicine. <b>See section 4 for more
information</b>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Look out for
important symptoms</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Some people
taking medicines for HIV infection develop other conditions, which can be
serious. You need to know about important signs and symptoms to look out for
while you are taking Lamivudine Teva Pharma B.V..</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read the
information &#8216;Other possible side effects of combination therapy for
HIV&#8217; in section 4 of this leaflet</span></b><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal'><b><span lang=EN-GB>Protect other people</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>HIV infection is
spread by sexual contact with someone who has the infection, or by transfer of
infected blood (for example, by sharing injection needles). You can still pass
on HIV when taking this medicine, although the risk is lowered by effective
antiretroviral therapy.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Discuss with your doctor the precautions needed to avoid infecting
other people.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other
medicines and Lamivudine Teva Pharma B.V.</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Tell your
doctor or pharmacist if you are taking,</span></b><span lang=EN-GB> have
recently taken or might take any other medicines, including herbal medicines or
other medicines you bought without a prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Remember to tell
your doctor or pharmacist if you begin taking a new medicine while you are
taking Lamivudine Teva Pharma B.V..</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>These
medicines should not be used with Lamivudine Teva Pharma B.V.:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines (usually liquids) containing sorbitol
and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if
taken regularly.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>other medicines containing lamivudine (used to
treat <b>HIV infection </b>or <b>hepatitis B infection</b>).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>emtricitabine (used to treat <b>HIV infection</b>).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high doses of <b>co-trimoxazole</b>, an
antibiotic.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cladribine (used to treat hairy cell leukaemia).</span></p>

<p class=Action style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><b><span lang=EN-GB>Tell your doctor</span></b><span
lang=EN-GB> if you are being treated with any of these.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Pregnancy</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
pregnant, think you may be pregnant, or are planning to have a baby, ask your
doctor about the risks and benefits to you and your baby of taking Lamivudine
Teva Pharma B.V..</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Lamivudine Teva Pharma B.V. and similar medicines may cause
side effects in unborn babies. If you have taken </span><span lang=EN-GB>Lamivudine
Teva Pharma B.V. <span style='color:black'>during your pregnancy, your doctor
may request regular blood tests and other diagnostic tests to monitor the
development of your child. In children whose mothers took NRTIs during
pregnancy, the benefit from the protection against HIV outweighed the risk of
side effects.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Women who are
HIV-positive must not breast-feed</span></b><span lang=EN-GB>, because HIV
infection can be passed on to the baby in breast milk.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A small amount
of the ingredients in <span style='color:black'>Lamivudine Teva Pharma B.V. </span>can
also pass into your breast milk.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
breast-feeding, or thinking about breast-feeding: <b>Talk to your doctor
immediately</b>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='color:black'>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Lamivudine Teva Pharma B.V. is unlikely to
affect your ability to drive or use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Lamivudine
Teva Pharma B.V.</span></b><b> contains sodium</b></p>

<p class=MsoNormal style='line-height:normal'>This medicine contains less than
1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially
&#8220;sodium-free&#8221;.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>How to take Lamivudine Teva Pharma B.V.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Always take this medicine exactly as your doctor has told you.</span></b><span
lang=EN-GB> Check with your doctor or pharmacist if you are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Swallow the tablets, with some water. Lamivudine Teva
Pharma B.V. can be taken with or without food.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>If you cannot swallow the tablets whole, you may crush and
combine them with a small amount of food or drink, and take all the dose
immediately.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=Action style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><b><span lang=EN-GB>Stay in regular contact with your
doctor</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Lamivudine Teva Pharma B.V. helps to control your condition. You
need to keep taking it every day to stop your illness getting worse. </span><span
lang=EN-GB>You may still develop other infections and illnesses linked to HIV infection.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Keep in touch with your doctor, and do not stop taking Lamivudine
Teva Pharma B.V.</span></b><span lang=EN-GB> without your doctor&#8217;s
advice.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>How much to take</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Adults, adolescents and children who weigh at least 25&nbsp;kg</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The usual dose of </span><span lang=EN-GB>Lamivudine Teva Pharma
B.V. is 300&nbsp;mg a day. This can be taken as either one 150&nbsp;mg tablet
twice a day (leaving approximately 12&nbsp;hours between each dose), or two 150&nbsp;mg
tablets once a day as advised by your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Children weighing at least 20</span></b><span lang=EN-GB>&nbsp;<b>kg
and less than 25</b>&nbsp;<b>kg</b></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The usual dose of </span><span lang=EN-GB>Lamivudine Teva Pharma
B.V. is 225&nbsp;mg a day. This can be given as 75&nbsp;mg (half a 150&nbsp;mg
tablet) in the morning and 150&nbsp; mg (one whole 150&nbsp;mg tablet) in the
evening, or 225&nbsp;mg (one and a half 150&nbsp;mg tablets) once a day as
advised by your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Children weighing at least 14</span></b><span lang=EN-GB>&nbsp;<b>kg
and less than 20</b>&nbsp;<b>kg</b></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The usual dose of </span><span lang=EN-GB>Lamivudine Teva Pharma
B.V. is 150&nbsp;mg a day. This can be given as 75&nbsp;mg (half a 150&nbsp;mg
tablet) twice a day (leaving approximately 12&nbsp;hours between each dose), or
150&nbsp;mg (one 150&nbsp;mg tablet) once a day as advised by your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>An oral solution is also available for the treatment of
children over 3&nbsp;months of age, or for people who need a lower dose than
usual, or who cannot take tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>If you or your child has a kidney problem</span></b><span
lang=EN-GB style='color:black'>, your dose may be altered.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Talk to your doctor </span></b><span lang=EN-GB
style='color:black'>if this applies to you or your child.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>If you take more Lamivudine Teva Pharma B.V. than you
should</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Accidentally
taking too much Lamivudine Teva Pharma B.V. is unlikely to cause any serious
problems. If you take too much, tell your doctor or your pharmacist, or contact
your nearest hospital emergency department for further advice.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you forget to take Lamivudine Teva Pharma B.V.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you forget to take a dose, take it as soon as you remember. Then
continue</span><span lang=EN-GB> your treatment as before. Do not take a double
dose to make up for a forgotten dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although not
everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>During HIV therapy there may be an increase in weight and in levels
of blood lipids and glucose. This is partly linked to restored health and life
style, and in the case of blood lipids sometimes to the HIV medicines
themselves. Your doctor will test for these changes.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>When you are being treated for HIV, it can be hard to tell whether a
symptom is a side effect of Lamivudine Teva Pharma B.V. or other medicines you
are taking, or an effect of the HIV disease itself. <b>So it is very important to
talk to your doctor about any changes in your health.</b></span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>As well as
the side effects listed below for Lamivudine Teva Pharma B.V.</span></b><span
lang=EN-GB>, other conditions can develop during combination therapy for HIV.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>It is important to read the information later in this section under
&#8216;Other possible side effects of combination therapy for HIV&#8217;.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Common side
effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>These may affect<b>
up to 1 in 10</b> people:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling sick (<i>nausea</i>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>being sick (<i>vomiting</i>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stomach pains</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tiredness, lack of energy</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever (high temperature)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>general feeling of being unwell</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain and discomfort</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty in sleeping (<i>insomnia</i>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>irritated or runny nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hair loss (<i>alopecia</i>).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Uncommon side
effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>These may affect<b>
up to 1 in 100</b> people:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Uncommon side
effects that may show up in blood tests are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a decrease in the number of cells involved in
blood clotting (<i>thrombocytopenia</i>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a low red blood cell count (<i>anaemia</i>) or
low white blood cell count (<i>neutropenia</i>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an increase in the level of liver enzymes.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Rare side
effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>These may affect
<b>up to 1 in 1000</b> people:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>serious allergic reaction
causing swelling of the face, tongue or throat which may cause difficulty in
swallowing or breathing</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the pancreas (<i>pancreatitis</i>)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breakdown of muscle tissue</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>liver disorders, such as jaundice, enlarged
liver or fatty liver, inflammation (<i>hepatitis</i>)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>A rare side effect that may show up in blood tests is:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol;
color:black'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an increase in an enzyme called amylase.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Very rare
side effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>These may affect
<b>up to 1 in 10,000</b> people:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lactic acidosis (excess lactic acid in the
blood)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tingling or numbness of the arms, legs, hands or
feet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A very rare side
effect that may show up in blood tests is:</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a failure of the bone marrow to produce new red
blood cells<i> (pure red cell aplasia)</i>.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you get
side effects</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Tell your doctor or pharmacist</span></b><span lang=EN-GB> if any of
the side effects gets severe or troublesome, or if you notice any side effects
not listed in this leaflet.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other
possible side effects of combination therapy for HIV</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Combination
therapy including Lamivudine Teva Pharma B.V. may cause other conditions to
develop during HIV treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Old
infections may flare up</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>People with
advanced HIV infection (AIDS) have weak immune systems, and are more likely to
develop serious infections (opportunistic infections). When these people start
treatment, they may find that old, hidden infections flare up, causing signs
and symptoms of inflammation. These symptoms are probably caused by the
body&#8217;s immune system becoming stronger, so that the body starts to fight
these infections.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In addition to
the opportunistic infections, autoimmune disorders (a condition that occurs
when the immune system attacks healthy body tissue) may also occur after you
start taking medicines for the treatment of your HIV infection. Autoimmune
disorders may occur many months after the start of treatment. If you notice any
symptoms of infection or other symptoms such as muscle weakness, weakness
beginning in the hands and feet and moving up towards the trunk of the body,
palpitations, tremor or hyperactivity, please inform your doctor immediately to
seek necessary treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you get any
symptoms of infection while you are taking Lamivudine Teva Pharma B.V.:</span></p>

<p class=Action style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><b><span lang=EN-GB>Tell your doctor immediately</span></b><span
lang=EN-GB>. Do not take other medicines for the infection without your
doctor&#8217;s advice.</span></p>

<p class=Action style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>You may have problems
with your bones</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Some people
taking combination therapy for HIV develop a condition called <i>osteonecrosis</i>.
With this condition, parts of the bone tissue die because of reduced blood
supply to the bone. People may be more likely to get this condition:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if they have been taking combination therapy for
a long time</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if they are also taking anti-inflammatory
medicines called corticosteroids</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if they drink alcohol</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if their immune systems are very weak</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if they are overweight.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Signs of
osteonecrosis include:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stiffness in the joints</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>aches and pains (especially in the hip, knee or
shoulder)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty moving.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you notice
any of these symptoms: <b>Tell your doctor</b>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoFooter><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Reporting of side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist.</span><span
lang=EN-GB style='color:red'> </span><span lang=EN-GB>This includes any
possible side effects not listed in this leaflet. You can also report side
effects directly via <span style='background:lightgrey'>the national reporting
system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>. By
reporting side effects you can help provide more information on the safety of
this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store
Lamivudine Teva Pharma B.V.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the container or carton and blister after EXP. The expiry date refers to the
last day of that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicinal product does not require any special storage
conditions</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how to throw away the medicines you no longer use. These
measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB
style='color:black'>Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Lamivudine Teva Pharma B.V. contains</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is lamivudine. Each
film-coated tablet contains 150&nbsp;mg.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are:</span></p>

<p class=MsoBlockText><span lang=EN-GB>Tablet core: Microcrystalline cellulose,
sodium starch glycolate, magnesium stearate. Tablet film coat: Hypromellose,
titanium dioxide (E171), macrogol, polysorbate 80, iron oxide yellow (E172),
iron oxide black (E172)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Lamivudine Teva Pharma B.V. looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Light grey, diamond shaped, biconvex film-coated tablet -
engraved with &#8220;L&nbsp;150&#8221; and breakline on one side and breakline
on the other.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Lamivudine Teva Pharma B.V. is </span><span lang=EN-GB>available in
aluminium blisters containing 20, 30, 60, 80, 90, 100 and 500 tablets or HDPE
containers containing 60 tablets.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Not all pack sizes may be marketed</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Teva B.V.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Swensweg 5</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>2031GA Haarlem</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva
Pharmaceutical Works Private Limited Company</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pallagi
&uacute;t 13</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Debrecen H-4042</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hungary</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Pharmachemie B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>2031 GA Haarlem</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=535
 style='width:401.4pt;margin-left:9.0pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span lang=FR style='font-size:11.0pt;color:windowtext'>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR>Teva Pharma Belgium N.V./S.A./AG</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel/T&eacute;l: +32 38207373</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>UAB Teva
  Baltics</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tel:
  +370 52660203</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal;text-autospace:
  none'><span style='color:black'>&#1058;&#1077;&#1074;&#1072;</span><span
  style='color:black'> </span><span style='color:black'>&#1060;&#1072;&#1088;&#1084;&#1072;</span>
  <span lang=BG>&#1045;&#1040;&#1044;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Te</span><span
  lang=RU>&#1083;: +</span><span lang=BG>359 2</span><span lang=EN-GB>4899585</span></p>
  <p class=Default><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>ratiopharm GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>Allemagne/Deutschland</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>T&eacute;l/Tel: +49 73140202</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>&#268;esk&aacute;
  republika</span></b></p>
  <p class=Default><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>Teva
  Pharmaceuticals CR, s.r.o.</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tel:
  +420 251007111</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>Magyarorsz&aacute;g</span></b></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Teva
  Gy&oacute;gyszergy&aacute;r Zrt.</span></p>
  <p class=Default><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>Tel:
  +36 12886400</span></p>
  <p class=Default><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span style='font-size:11.0pt;color:windowtext'>Danmark</span></b></p>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Teva Denmark
  A/S</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tlf:
  +45 44985511</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Teva Pharmaceuticals Ireland</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>L-Irlanda</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +353 </span><span
  lang=EN-GB>19127700</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>ratiopharm GmbH</span></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>Tel:
  +49 73140202</span></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span lang=NL style='font-size:11.0pt;color:windowtext'>Nederland</span></b></p>
  <p class=MsoNormal style='margin-left:-1.15pt;line-height:normal;text-autospace:
  none'><span lang=NL>Teva Nederland B.V.</span></p>
  <p class=Default><span lang=NL style='font-size:11.0pt;color:windowtext'>Tel:
  +31 8000228400</span></p>
  <p class=Default><span lang=NL style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NL>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>UAB Teva Baltics Eesti filiaal</span></p>
  <p class=Default><span lang=NL style='font-size:11.0pt;color:windowtext'>Tel:
  </span><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>+372
  6610801</span></p>
  <p class=Default><span lang=NL style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b>Norge</b></p>
  <p class=MsoNormal style='line-height:normal'>Teva Norway AS</p>
  <p class=MsoNormal style='line-height:normal'>Tlf: +47 66775590</p>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specifar
  A.B.E.E.</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&#932;&#951;&#955;:
  +</span><span lang=EL style='font-size:11.0pt;color:windowtext'>30 21</span><span
  lang=DE style='font-size:11.0pt;color:windowtext'>18805000</span></p>
  <p class=Default><span lang=IS style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1970070</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Teva Pharma,
  S.L.U</span></p>
  <p class=Default><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>Tel:
  +34 913873280</span></p>
  <p class=Default><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Teva
  Pharmaceuticals Polska Sp. z o.o.</span></p>
  <p class=MsoHeader><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tel:
  +48 223459300</span></p>
  <p class=MsoHeader><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva
  Sant&eacute;</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>T&eacute;l:
  +33 155917800</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Portugal</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Teva Pharma - Produtos
  Farmac&ecirc;uticos, Lda</span></p>
  <p class=MsoHeader><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tel</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>:
  +351 214767550</span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Pliva Hrvatska d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +385
  13720000</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Teva
  Pharmaceuticals S.R.L</span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tel:
  +40 212306524</span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva
  Pharmaceuticals Ireland</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +353 19127700</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Pliva Ljubljana d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +386 15890390</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='line-height:normal'>Teva Finland<span lang=EN-GB>
  Oy</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Finnland</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>S&iacute;mi:
  +358 201805900</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva
  Pharmaceuticals Slovakia s.r.o.</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tel:
  +421 257267911</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Teva Italia
  S.r.l.</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tel:
  +39 028917981</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b>Suomi/Finland</b></p>
  <p class=MsoNormal style='line-height:normal'>Teva Finland Oy</p>
  <p class=MsoNormal style='line-height:normal'>Puh/Tel: +358 201805900</p>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'>Specifar A.B.E.E.</p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&#932;&#951;&#955;:
  +</span><span lang=EL style='font-size:11.0pt;color:windowtext'>30 21</span><span
  lang=DE style='font-size:11.0pt;color:windowtext'>18805000</span></p>
  <p class=Default><span lang=IS style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Teva Sweden AB</span></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>Tel:
  +46 42121100</span></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>UAB
  Teva Baltics fili&#257;le Latvij&#257;</span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tel:
  +371 67323666</span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva UK
  Limited</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tel:
  +44 1977628500</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in </span></b><span lang=EN-GB>{MM/YYYY}.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: </span><span lang=EN-GB style='color:blue'>http://www.ema.europa.eu/.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB style='color:black'>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Lamivudine Teva Pharma B.V. 300 mg film-coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>lamivudine</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start taking this medicine </span><span
lang=EN-GB style='color:black'>because it contains important information for
you</span><span lang=EN-GB>.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness are
the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet.See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Lamivudine Teva Pharma
B.V. is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB
style='color:black'>What you need to know b</span><span lang=EN-GB>efore you
take Lamivudine Teva Pharma B.V.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Lamivudine Teva
Pharma B.V.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Lamivudine Teva
Pharma B.V.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB
style='color:black'>Contents of the pack and other</span><span lang=EN-GB>
information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt;line-height:normal'><b><span
lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What Lamivudine Teva Pharma B.V. is and
what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Lamivudine
Teva Pharma B.V. is used to treat HIV (human immunodeficiency virus) infection
in adults and children</span></b><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The active
ingredient in Lamivudine Teva Pharma B.V. is lamivudine. Lamivudine Teva Pharma
B.V. is a type of medicine known as an antiretroviral. It belongs to a group of
medicines called <i>nucleoside analogue reverse transcriptase inhibitors
(NRTIs)</i>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. does not completely cure HIV infection; it reduces the amount of
virus in your body, and keeps it at a low level. It also increases the CD4 cell
count in your blood. CD4 cells are a type of white blood cells, that are
important in helping your body to fight infection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not everyone
responds to treatment with Lamivudine Teva Pharma B.V. in the same way. Your
doctor will monitor the effectiveness of your treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB
style='color:black'>What you need to know b</span><span lang=EN-GB>efore you
take Lamivudine Teva Pharma B.V.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not take
Lamivudine Teva Pharma B.V.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol;
color:black'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you are <b>allergic</b>
to lamivudine or any of the other ingredients of this medicine (listed in section
6).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Check with your doctor</span></b><span lang=EN-GB> if you think this
applies to you.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='color:black'>Warnings and precautions </span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>Talk to your doctor or pharmacist before taking </span><span
lang=EN-GB>Lamivudine Teva Pharma B.V..</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Some people taking Lamivudine Teva Pharma B.V. or other combination
treatments for HIV are more at risk of serious side effects. You need to be
aware of the extra risks:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol;color:black'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you have ever had <b>liver
disease</b>, including hepatitis B or C (if you have hepatitis B infection, do not
stop Lamivudine Teva Pharma B.V. without your doctor&#8217;s advice, as your
hepatitis may come back)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol;color:black'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you are seriously <b>overweight</b>
(especially if you are a woman)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol;
color:black'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>if you or your child has a kidney problem,</span></b><span
lang=EN-GB> your dose may be altered.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='color:black'>Talk to your doctor if any of these apply to you</span></b><span
lang=EN-GB style='color:black'>. You may need extra check-ups, including blood
tests, while you are taking your medicine. <b>See section 4 for more
information</b>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Look out for
important symptoms</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Some people
taking medicines for HIV infection develop other conditions, which can be
serious. You need to know about important signs and symptoms to look out for
while you are taking Lamivudine Teva Pharma B.V..</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read the
information &#8216;Other possible side effects of combination therapy for
HIV&#8217; in section 4 of this leaflet</span></b><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal'><b><span lang=EN-GB>Protect other people</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>HIV infection is
spread by sexual contact with someone who has the infection, or by transfer of
infected blood (for example, by sharing injection needles). You can still pass
on HIV when taking this medicine, although the risk is lowered by effective
antiretroviral therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Discuss with
your doctor the precautions needed to avoid infecting other people.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other
medicines and Lamivudine Teva Pharma B.V.</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Tell your
doctor or pharmacist if you are taking,</span></b><span lang=EN-GB> have
recently taken or might take any other medicines, including herbal medicines or
other medicines you bought without a prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Remember to tell
your doctor or pharmacist if you begin taking a new medicine while you are
taking Lamivudine Teva Pharma B.V..</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>These
medicines should not be used with Lamivudine Teva Pharma B.V.:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines (usually liquids) containing sorbitol
and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if
taken regularly.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>other medicines containing lamivudine, (used to
treat <b>HIV infection</b> or <b>hepatitis B infection)</b>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>emtricitabine (used to treat <b>HIV infection</b>).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.5pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high doses of <b>co-trimoxazole</b>, an
antibiotic.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.5pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cladribine (used to treat hairy cell leukaemia).</span></p>

<p class=Action style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><b><span lang=EN-GB>Tell your doctor</span></b><span
lang=EN-GB> if you are being treated with any of these.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Pregnancy</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
pregnant,</span><span lang=EN-GB> think you may be pregnant, or are planning to
have a baby, ask your doctor about the risks and benefits to you and your baby
of taking Lamivudine Teva Pharma B.V..</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Lamivudine Teva Pharma B.V. and similar medicines may cause
side effects in unborn babies. If you have taken </span><span lang=EN-GB>Lamivudine
Teva Pharma B.V. <span style='color:black'>during your pregnancy, your doctor
may request regular blood tests and other diagnostic tests to monitor the
development of your child. In children whose mothers took NRTIs during
pregnancy, the benefit from the protection against HIV outweighed the risk of
side effects.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Women who are
HIV-positive must not breast-feed,</span></b><span lang=EN-GB> because HIV infection
can be passed on to the baby in breast milk.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A small amount
of the ingredients in <span style='color:black'>Lamivudine Teva Pharma B.V. </span>can
also pass into your breast milk.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
breast-feeding, or thinking about breast-feeding: <b>Talk to your doctor
immediately</b>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='color:black'>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Lamivudine Teva Pharma B.V. is unlikely to
affect your ability to drive or use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Lamivudine
Teva Pharma B.V.</span></b><b> contains sodium</b></p>

<p class=MsoNormal style='line-height:normal'>This medicine contains less than
1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially
&#8220;sodium-free&#8221;.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Lamivudine Teva
Pharma B.V.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Always take this medicine exactly as your doctor has told you</span></b><span
lang=EN-GB>. Check with your doctor or pharmacist if you are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Swallow the
tablet with some water. Lamivudine Teva Pharma B.V. can be taken with or
without food.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>If you cannot swallow the tablet whole, you may
crush and combine it with a small amount of food or drink, and take all the
dose immediately.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Action style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><b><span lang=EN-GB>Stay in regular contact with your
doctor</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine Teva
Pharma B.V. helps to control your condition. You need to keep taking it every
day to stop your illness getting worse. You may still develop other infections
and illnesses linked to HIV infection.</span></p>

<p class=Action style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><b><span lang=EN-GB>Keep in touch with your doctor, and do not
stop taking Lamivudine Teva Pharma B.V.</span></b><span lang=EN-GB> without
your doctor&#8217;s advice.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='color:black'>How much to take</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Adults, adolescents and children who weigh at least 25&nbsp;kg</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The usual dose is one 300<b>&nbsp;</b>mg tablet once a day. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>A 150<b>&nbsp;</b>mg strength </span><span lang=EN-GB>Lamivudine
Teva Pharma B.V. tablet is also available for the treatment of children from 3<b>&nbsp;</b>months
of age who weigh less than 25<b>&nbsp;</b>kg.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>An </span><span lang=EN-GB style='color:black'>oral
solution is also </span><span lang=EN-GB style='color:black'>available for the
treatment of children over 3 months of age, or for people who need a lower dose
than usual, or who cannot take tablets.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>If you or your child has a kidney problem</span></b><span
lang=EN-GB style='color:black'>, your dose may be altered.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Talk to your doctor </span></b><span lang=EN-GB
style='color:black'>if this applies to you or your child.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you take more Lamivudine Teva Pharma B.V. than you should</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Accidentally
taking too much Lamivudine Teva Pharma B.V. is unlikely to cause any serious
problems.</span><span lang=EN-GB> If you take too much, tell your doctor or your
pharmacist, or contact your nearest hospital emergency department for further
advice.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you forget to take Lamivudine Teva Pharma B.V.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you forget to take a dose, take it as soon as you remember. Then
continue your treatment as before. Do not take a double dose to make up for a
forgotten dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>During HIV therapy there may be an increase in weight and in levels
of blood lipids and glucose. This is partly linked to restored health and life
style, and in the case of blood lipids sometimes to the HIV medicines
themselves. Your doctor will test for these changes.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>When you are being treated for HIV, it can be hard to tell whether a
symptom is a side effect of Lamivudine Teva Pharma B.V. or other medicines you
are taking, or an effect of the HIV disease itself. <b>So it is very important to
talk to your doctor about any changes in your health.</b></span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>As well as
the side effects listed below for Lamivudine Teva Pharma B.V.</span></b><span
lang=EN-GB>, other conditions can develop during combination therapy for HIV.</span></p>

<p class=Action style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><span lang=EN-GB>It is important to read the information
later in this section under &#8216;Other possible side effects of combination
therapy for HIV&#8217;.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Common side
effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>These may affect<b>
up to 1 in 10</b> people:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling sick (<i>nausea</i>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>being sick (<i>vomiting</i>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stomach pains</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tiredness, lack of energy</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever (high temperature)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>general feeling of being unwell</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain and discomfort</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty in sleeping (<i>insomnia</i>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>irritated or runny nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hair loss (<i>alopecia</i>).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Uncommon side
effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>These may affect<b>
up to 1 in 100</b> people:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Uncommon side
effects that may show up in blood tests are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a decrease in the number of cells involved in
blood clotting (<i>thrombocytopenia</i>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a low red blood cell count (<i>anaemia</i>) or
low white blood cell count (<i>neutropenia</i>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an increase in the level of liver enzymes.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Rare side
effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>These may affect
<b>up to 1 in 1000</b> people:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>serious allergic reaction
causing swelling of the face, tongue or throat which may cause difficulty in
swallowing or breathing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the pancreas <i>(pancreatitis)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breakdown of muscle tissue</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>liver disorders, such as jaundice, enlarged
liver or fatty liver, inflammation (<i>hepatitis</i>)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A rare side
effect that may show up in blood tests is:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an increase in an enzyme called amylase.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Very rare
side effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>These may affect
<b>up to 1 in 10,000</b> people:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lactic acidosis (excess lactic acid in the
blood)</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tingling or numbness of the arms, legs, hands or
feet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A very rare side
effect that may show up in blood tests is:</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a failure of the bone marrow to produce new red
blood cells<i> (pure red cell aplasia)</i>.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you get
side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Tell your doctor or pharmacist</span></b><span lang=EN-GB> if any of
the side effects gets severe or troublesome, or if you notice any side effects
not listed in this leaflet.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other
possible side effects of combination therapy for HIV</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Combination
therapy including Lamivudine Teva Pharma B.V. may cause other conditions to
develop during HIV treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Old
infections may flare up</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>People with
advanced HIV infection (AIDS) have weak immune systems, and are more likely to
develop serious infections (opportunistic infections). When these people start
treatment, they may find that old, hidden infections flare up, causing signs
and symptoms of inflammation. These symptoms are probably caused by the body&#8217;s
immune system becoming stronger, so that the body starts to fight these
infections.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In addition to
the opportunistic infections, autoimmune disorders (a condition that occurs
when the immune system attacks healthy body tissue) may also occur after you start
taking medicines for the treatment of your HIV infection. Autoimmune disorders
may occur many months after the start of treatment. If you notice any symptoms
of infection or other symptoms such as muscle weakness, weakness beginning in
the hands and feet and moving up towards the trunk of the body, palpitations,
tremor or hyperactivity, please inform your doctor immediately to seek
necessary treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you get any
symptoms of infection while you are taking Lamivudine Teva Pharma B.V.:</span></p>

<p class=Action style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><b><span lang=EN-GB>Tell your doctor immediately</span></b><span
lang=EN-GB>. Do not take other medicines for the infection without your
doctor&#8217;s advice.</span></p>

<p class=Action style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>You may have
problems with your bones</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Some people
taking combination therapy for HIV develop a condition called <i>osteonecrosis</i>.
With this condition, parts of the bone tissue die because of reduced blood
supply to the bone. People may be more likely to get this condition:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if they have been taking combination therapy for
a long time</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if they are also taking anti-inflammatory
medicines called corticosteroids</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if they drink alcohol</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if their immune systems are very weak</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if they are overweight.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Signs of
osteonecrosis include:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stiffness in the joints</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>aches and pains (especially in the hip, knee or
shoulder)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty moving.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you notice
any of these symptoms: <b>Tell your doctor</b>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoFooter><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Reporting of side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist.</span><span
lang=EN-GB style='color:red'> </span><span lang=EN-GB>This includes any
possible side effects not listed in this leaflet. You can also report side
effects directly via <span style='background:lightgrey'>the national reporting system
listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>. By
reporting side effects you can help provide more information on the safety of
this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store
Lamivudine Teva Pharma B.V.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the container or carton and blister after EXP. The expiry date refers to the
last day of that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicinal product does not require any special storage
conditions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how to throw away the medicines you no longer use. These
measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB
style='color:black'>Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Lamivudine Teva Pharma B.V. contains</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is lamivudine. Each
film-coated tablet contains 300&nbsp;mg.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are:</span></p>

<p class=MsoBlockText><span lang=EN-GB>Tablet core: Microcrystalline cellulose,
sodium starch glycolate, magnesium stearate. Tablet film coat: Hypromellose,
titanium dioxide (E171), macrogol, polysorbate 80, iron oxide yellow (E172),
iron oxide black (E172)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Lamivudine Teva Pharma B.V. looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Grey, diamond
shaped, biconvex film-coated tablet &#8211; engraved with
&#8220;L&nbsp;300&#8221; on one side and plain on the other</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Lamivudine Teva Pharma B.V. is </span><span lang=EN-GB>available in
aluminium blisters containing 20, 30, 60, 80, 90, 100 and 500 tablets or HDPE containers
containing 30 tablets.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Not all pack sizes may be marketed</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Teva B.V.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Swensweg 5</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>2031GA Haarlem</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva
Pharmaceutical Works Private Limited Company</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pallagi
&uacute;t 13</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Debrecen H-4042</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hungary</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Pharmachemie B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>2031 GA Haarlem</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=535
 style='width:401.4pt;margin-left:9.0pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span lang=FR style='font-size:11.0pt;color:windowtext'>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR>Teva Pharma Belgium N.V./S.A./AG</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel/T&eacute;l: +32 38207373</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>UAB Teva
  Baltics</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tel:
  +370 52660203</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal;text-autospace:
  none'><span style='color:black'>&#1058;&#1077;&#1074;&#1072;</span><span
  style='color:black'> </span><span style='color:black'>&#1060;&#1072;&#1088;&#1084;&#1072;</span>
  <span lang=BG>&#1045;&#1040;&#1044;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Te</span><span
  lang=RU>&#1083;: +</span><span lang=BG>359 2</span><span lang=EN-GB>4899585</span></p>
  <p class=Default><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>ratiopharm GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>Allemagne/Deutschland</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>T&eacute;l/Tel: +49 73140202</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>&#268;esk&aacute;
  republika</span></b></p>
  <p class=Default><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>Teva
  Pharmaceuticals CR, s.r.o.</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tel:
  +420 251007111</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>Magyarorsz&aacute;g</span></b></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Teva
  Gy&oacute;gyszergy&aacute;r Zrt.</span></p>
  <p class=Default><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>Tel:
  +36 12886400</span></p>
  <p class=Default><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span style='font-size:11.0pt;color:windowtext'>Danmark</span></b></p>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Teva Denmark
  A/S</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tlf:
  +45 44985511</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Teva Pharmaceuticals Ireland</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>L-Irlanda</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +353 </span><span
  lang=EN-GB>19127700</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>ratiopharm GmbH</span></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>Tel:
  +49 73140202</span></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=Default><b><span lang=NL style='font-size:11.0pt;color:windowtext'>Nederland</span></b></p>
  <p class=MsoNormal style='margin-left:-1.15pt;line-height:normal;text-autospace:
  none'><span lang=NL>Teva Nederland B.V.</span></p>
  <p class=Default><span lang=NL style='font-size:11.0pt;color:windowtext'>Tel:
  +31 8000228400</span></p>
  <p class=Default><span lang=NL style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NL>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>UAB Teva Baltics Eesti filiaal</span></p>
  <p class=Default><span lang=NL style='font-size:11.0pt;color:windowtext'>Tel:
  </span><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>+372
  6610801</span></p>
  <p class=Default><span lang=NL style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b>Norge</b></p>
  <p class=MsoNormal style='line-height:normal'>Teva Norway AS</p>
  <p class=MsoNormal style='line-height:normal'>Tlf: +47 66775590</p>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specifar
  A.B.E.E.</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&#932;&#951;&#955;:
  +</span><span lang=EL style='font-size:11.0pt;color:windowtext'>30 21</span><span
  lang=DE style='font-size:11.0pt;color:windowtext'>18805000</span></p>
  <p class=Default><span lang=IS style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1970070</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Teva Pharma,
  S.L.U</span></p>
  <p class=Default><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>Tel:
  +34 913873280</span></p>
  <p class=Default><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Teva
  Pharmaceuticals Polska Sp. z o.o.</span></p>
  <p class=MsoHeader><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tel:
  +48 223459300</span></p>
  <p class=MsoHeader><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva
  Sant&eacute;</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>T&eacute;l:
  +33 155917800</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Portugal</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Teva Pharma -
  Produtos Farmac&ecirc;uticos, Lda</span></p>
  <p class=MsoHeader><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tel</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>:
  +351 214767550</span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Pliva Hrvatska d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +385
  13720000</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Teva
  Pharmaceuticals S.R.L</span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tel:
  +40 212306524</span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva
  Pharmaceuticals Ireland</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +353 19127700</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Pliva Ljubljana d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +386 15890390</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='line-height:normal'>Teva Finland<span lang=EN-GB>
  Oy</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Finnland</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>S&iacute;mi:
  +358 201805900</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva
  Pharmaceuticals Slovakia s.r.o.</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tel:
  +421 257267911</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Teva Italia
  S.r.l.</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tel:
  +39 028917981</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b>Suomi/Finland</b></p>
  <p class=MsoNormal style='line-height:normal'>Teva Finland Oy</p>
  <p class=MsoNormal style='line-height:normal'>Puh/Tel: +358 201805900</p>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'>Specifar A.B.E.E.</p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&#932;&#951;&#955;:
  +</span><span lang=EL style='font-size:11.0pt;color:windowtext'>30 21</span><span
  lang=DE style='font-size:11.0pt;color:windowtext'>18805000</span></p>
  <p class=Default><span lang=IS style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Teva Sweden AB</span></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>Tel:
  +46 42121100</span></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>UAB
  Teva Baltics fili&#257;le Latvij&#257;</span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tel:
  +371 67323666</span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva UK
  Limited</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tel:
  +44 1977628500</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>This leaflet was last revised in </span></b><span lang=EN-GB>{MM/YYYY}.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: </span><span lang=EN-GB><span style='color:blue'>http://www.ema.europa.eu/.</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
